ITC kicks off trials of nasal spray for Covid prevention
Business Standard|November 26, 2021
Diversified conglomerate ITC has started clinical trials of a nasal spray for Covid19 prevention.
ISHITA AYAN DUTT & SOHINI DAS

An ITC spokesperson confirmed the development but said the company is “unable to share more details at the current moment as the clinical trials are underway".

Sources, however, indicated that the product was being steered by ITC Life Sciences and Technology Centre (LSTC) in Bengaluru. The spray has the potential to be effective in preventing infection as well as transmission of Covid-19. Internal trials had also found it to be effective against other viruses like common cold. The trials could take about three months, they said. The company has received approvals from ethics committees and is registered with Clinical Trial Registry - India, they added.

Continue reading your story on the app

Continue reading your story in the newspaper

MORE STORIES FROM BUSINESS STANDARDView All

Netflix Needs Its KBC Lest It Lose The India Plot

It began innocuously. On Thursday, Netflix, Inc. had an earnings call for the results of its fourth quarter of 2021. Nidhi Gupta, an analyst with Fidelity Management & Research Co, asked Gregory Peters, chief operating officer and chief product officer, what it was trying to achieve with a (30-60 per cent) price drop in India.

3 mins read
Business Standard
January 24, 2022

Bulking up IFSC

A wide-ranging and ambitious expansion of its remit is expected in the Budget

4 mins read
Business Standard
January 24, 2022

‘Rural sales value positive; volumes have declined

Q&A SANJIV MEHTA, chairman and MD of Hindustan Unilever (HUL), considers health, hygiene and wellbeing as the new areas of growth for the fast-moving consumer goods (FMCG) major over the next five years. In an exclusive interview with Sharleen D'Souza and Vishal Chhabria, he shares his expectation of commodity prices cooling off in the second half of 2022 which should lead to the return of volume-led growth. Edited excerpts:

1 min read
Business Standard
January 24, 2022

Govt firms asked to declare market value of assets

Measure seen as a bid to boost investor confidence in PSUS

2 mins read
Business Standard
January 24, 2022

Doing good with emerging technologies

Artificial intelligence, machine learning and data analytics are increasingly being used to drive the social good, reports Shivani Shinde

3 mins read
Business Standard
January 24, 2022

Companies hope for sops in Budget to boost capex

Indian companies are expecting generous tax Budget that will help them invest more in building capacities in the coming years.

2 mins read
Business Standard
January 24, 2022

Double-digit loan growth may buoy ICICI Bank profit

ICICI Bank is expected to post a healthy profit for the December quarter (Q3FY22), helped by a double-digit growth in loans, when it reports its earnings on Saturday.

1 min read
Business Standard
January 22, 2022

Zomato hits record low, m-cap falls below ₹1trn

Shares of Zomato continued to wilt under selling pressure on Friday, falling 9 per cent on the BSE to ₹113.75, the lowest close since its listing on July 23, 2021.

1 min read
Business Standard
January 22, 2022

Shoppers Stop hits 52-week high

Shares of Shoppers Stop ended 5 per cent higher at ₹378.65 on the BSE on Friday in an otherwise weak market after the company reported a strong operational performance for the December quarter (Q3FY22).

1 min read
Business Standard
January 22, 2022

Separate 5G band & aviation radar frequency: Airtel

Experts say that unlike the US, India already has a large separation between the two bands

2 mins read
Business Standard
January 22, 2022
RELATED STORIES

'IT Chapter 2' Is A Big-Screen Fun House

It can be a cheesy thing when a novel is split up and spread out over a handful of films, but Stephen King’s “It” is not one of those books.

3 mins read
AppleMagazine
September 06, 2019

State plans norms to curb rampant use of monoclonal antibodies

The rampant use of mono-clonal antibodies on Co-vid patients has prompted the state to frame a protocol on use of the cocktail drug that costs Rs 60,000 to Rs 70,000 per dose.

3 mins read
The Times of India Mumbai
January 15, 2022

As cases soar, cry for cocktail cure

As Covid cases across the city soar, so has the demand for cocktail therapy as compared to the second wave.

2 mins read
The Free Press Journal
January 03. 2022

PICK & CHOOSE

Two vaccines, Covid oral pill get DGCI nod

1 min read
The Free Press Journal
December 29, 2021

Cipla launches India's first pneumotach-based wireless spirometer

Cipla’s Spirofy is a result of five years of in-house research by the Integrated Product Development (IPD) team, and it aims to transform OAD diagnosis in India.

1 min read
BioSpectrum Asia
BioSpectrum Asia Dec 2021

THE SHORT SQUEEZE

Replacing toothpaste tubes with tabs can enable the hospitality industry to take a huge cooperative step forward towards sustainability

3 mins read
Hotelier India
November 2021

ऊंची लागत की मार से महंगे हुए एफएमसीजी उत्पाद

उत्पादों के दाम बढ़ने से एफएमसीजी कंपनियों की बिक्री हो सकती है प्रभावित, मगर उनके पास कोई और विकल्प नहीं

1 min read
Business Standard - Hindi
November 27, 2021

Remogliflozin, vildagliptin, metformin FDC approved for Type 2 Diabetes in India

Mumbai-based drumaker Glenmark Pharmaceuticals received approval for its fixed dose combination (FDC) of remogliflozin (100 mg), vildagliptin (50 mg) and metformin (500/ 1000 mg from the Drug Controller General of India.

3 mins read
Future Medicine India
November 2021

The press is making it harder for women to come forward

Last Monday, Conservative MP Caroline Nokes told Sky News that Stanley Johnson, the prime minister’s father, had once smacked her “on the backside about as hard as he could” at an event.

3 mins read
The Independent
November 24, 2021

‘You cannot reach people effectively if you are not understood'

WITH a career sprawling over four decades, Indian politician and writer Shashi Tharoor has penned a number of books on diverse themes.

1 min read
The Morning Standard
November 18, 2021